Literature DB >> 14453744

The radical radiotherapy of regionally localized Hodgkin's disease.

H S KAPLAN.   

Abstract

Entities:  

Keywords:  HODGKIN'S DISEASE/radiotherapy

Mesh：

Year:  1962        PMID： 14453744     DOI： 10.1148/78.4.553

Source DB:  PubMed          Journal:  Radiology        ISSN： 0033-8419            Impact factor:   11.105


× No keyword cloud information.
  37 in total

1.  Staging laparotomy in non-Hodgkin's lymphoma.

Authors:  E M Moran; J E Ultmann; D J Ferguson; P B Hoffer; K Ranniger; H Rappaport
Journal:  Br J Cancer Suppl       Date:  1975-03

Review 2.  Changing role and decreasing size: current trends in radiotherapy for Hodgkin's disease.

Authors:  Joachim Yahalom
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

3.  ABVD vs. radiotherapy in early stage Hodgkin's lymphoma: A critical look at the NCIC HD.6 trial.

Authors:  F Wenz; Y Abo-Madyan; G Welzel; F A Giordano
Journal:  Strahlenther Onkol       Date:  2012-08       Impact factor: 3.621

Review 4.  Does radiotherapy still have a place in Hodgkin lymphoma?

Authors:  Joachim Yahalom
Journal:  Curr Hematol Malig Rep       Date:  2009-07       Impact factor: 3.952

5.  Chemotherapy of Hodgkin's Disease with Cyclophosphamide, Vinblastine, and Procarbazine.

Authors:  G H Fairley; M J Patterson; R B Scott
Journal:  Br Med J       Date:  1966-07-09

6.  Hodgkin's Disease: Treatment and Prognosis.

Authors:  V W Ing
Journal:  Can Fam Physician       Date:  1982-03       Impact factor: 3.275

7.  Treatment outcome of limited stage Hodgkin's disease.

Authors:  Jung Hun Kang; Yong Chan Ahn; Won Seog Kim; Won Ki Kang
Journal:  Cancer Res Treat       Date:  2005-02-28       Impact factor: 4.679

8.  [Standard versus individually planned irradiation field in radiotherapy of infradiaphragmatic lymph node sites].

Authors:  M Nevinny-Stickel; S Ennemoser; I Bangerl; D zur Nedden; P Lukas
Journal:  Strahlenther Onkol       Date:  1998-07       Impact factor: 3.621

Review 9.  Balancing risks and benefits of therapy for patients with favorable-risk limited-stage Hodgkin lymphoma: the role of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy alone.

Authors:  Annette E Hay; Ralph M Meyer
Journal:  Hematol Oncol Clin North Am       Date:  2014-02       Impact factor: 3.722

Review 10.  Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

Authors:  Gita Thanarajasingam; Lori M Minasian; Frederic Baron; Franco Cavalli; R Angelo De Claro; Amylou C Dueck; Tarec C El-Galaly; Neil Everest; Jan Geissler; Christian Gisselbrecht; John Gribben; Mary Horowitz; S Percy Ivy; Caron A Jacobson; Armand Keating; Paul G Kluetz; Aviva Krauss; Yok Lam Kwong; Richard F Little; Francois-Xavier Mahon; Matthew J Matasar; María-Victoria Mateos; Kristen McCullough; Robert S Miller; Mohamad Mohty; Philippe Moreau; Lindsay M Morton; Sumimasa Nagai; Simon Rule; Jeff Sloan; Pieter Sonneveld; Carrie A Thompson; Kyriaki Tzogani; Flora E van Leeuwen; Galina Velikova; Diego Villa; John R Wingard; Sophie Wintrich; John F Seymour; Thomas M Habermann
Journal:  Lancet Haematol       Date:  2018-06-18       Impact factor: 18.959
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.